Dossier
cellular reprogramming
Coverage of cellular reprogramming in the Nexus archive.
- Longevity medicine's do-or-die moment
The first human trial of an experimental gene therapy aims to test the safety of cellular reprogramming to rejuvenate aging cells, with initial focus on treating glaucoma. The trial, sponsored by Life Biosciences co-founded by David Sinclair, represents a critical step in validating the potential of epigenetic reprogramming to address age-related diseases.
- World-first: therapy to make cells young again given to a person
The first person has received a therapy in a clinical trial aimed at rejuvenating aging cells through cellular reprogramming. This marks a world-first advancement in cellular rejuvenation research.